POLE2 promotes osteosarcoma progression by enhancing the stability of CD44.
Baichuan WangHongzhi HuXiaohui WangZengwu ShaoDeyao ShiFashuai WuJianxiang LiuZhicai ZhangJuan LiZhidao XiaWeijian LiuQiang WuPublished in: Cell death discovery (2024)
Osteosarcoma (OS) is the most prevalent primary malignancy of bone in children and adolescents. It is extremely urgent to develop a new therapy for OS. In this study, the GSE14359 chip from the GEO database was used to screen differentially expressed genes in OS. DNA polymerase epsilon 2 (POLE2) was confirmed to overexpress in OS tissues and cell lines by immunohistochemical staining, qPCR and Western blot. Knockdown of POLE2 inhibited the proliferation and migration of OS cells in vitro, as well as the growth of tumors in vivo, while the apoptosis rate was increased. Bioinformatics analysis revealed that CD44 and Rac signaling pathway were the downstream molecule and pathway of POLE2, which were inhibited by knockdown of POLE2. POLE2 reduced the ubiquitination degradation of CD44 by acting on MDM2. Moreover, knockdown of CD44 inhibited the tumor-promoting effects of POLE2 overexpression on OS cells. In conclusion, POLE2 augmented the expression of CD44 via inhibiting MDM2-mediated ubiquitination, and then activated Rac signaling pathway to influence the progression of OS, indicating that POLE2/CD44 might be potential targets for OS treatment.
Keyphrases
- signaling pathway
- induced apoptosis
- cell cycle arrest
- nk cells
- pi k akt
- endoplasmic reticulum stress
- bioinformatics analysis
- poor prognosis
- cell proliferation
- epithelial mesenchymal transition
- cell death
- south africa
- risk assessment
- bone mineral density
- circulating tumor cells
- postmenopausal women
- smoking cessation